{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T23:35:57Z","timestamp":1780356957944,"version":"3.54.1"},"update-to":[{"DOI":"10.1002\/14651858.cd004523.pub3","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2022,5,3]],"date-time":"2022-05-03T00:00:00Z","timestamp":1651536000000}}],"reference-count":242,"publisher":"Wiley","issue":"7","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd004523.pub4","type":"journal-article","created":{"date-parts":[[2022,5,3]],"date-time":"2022-05-03T10:41:42Z","timestamp":1651574502000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Risedronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women"],"prefix":"10.1002","volume":"2022","author":[{"given":"George A","family":"Wells","sequence":"additional","affiliation":[{"name":"School of Epidemiology and Public Health; University of Ottawa; Ottawa Canada"},{"name":"Cardiovascular Research Methods Centre; University of Ottawa Heart Institute; Ottawa Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu-Ching","family":"Hsieh","sequence":"additional","affiliation":[{"name":"Cardiovascular Research Methods Centre; University of Ottawa Heart Institute; Ottawa Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carine","family":"Zheng","sequence":"additional","affiliation":[{"name":"Cardiovascular Research Methods Centre; University of Ottawa Heart Institute; Ottawa Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joan","family":"Peterson","sequence":"additional","affiliation":[{"name":"Clinical Epidemiology Program; Ottawa Hospital Research Institute; Ottawa Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenfei","family":"Liu","sequence":"additional","affiliation":[{"name":"Cardiovascular Research Methods Centre; University of Ottawa Heart Institute; Ottawa Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shannon E","family":"Kelly","sequence":"additional","affiliation":[{"name":"School of Epidemiology and Public Health; University of Ottawa; Ottawa Canada"},{"name":"Cardiovascular Research Methods Centre; University of Ottawa Heart Institute; Ottawa Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Tugwell","sequence":"additional","affiliation":[{"name":"School of Epidemiology and Public Health; University of Ottawa; Ottawa Canada"},{"name":"Clinical Epidemiology Program; Ottawa Hospital Research Institute; Ottawa Canada"},{"name":"Department of Medicine, Faculty of Medicine; University of Ottawa; Ottawa Canada"},{"name":"WHO Collaborating Centre for Knowledge Translation and Health Technology Assessment in Health Equity; Bruy\u00e8re Research Institute; Ottawa Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2022,5,3]]},"reference":[{"key":"10.1002\/14651858.CD004523.pub4-BIB0001|cit1","unstructured":"Akyol Y Tander B Alayli G Durmus D Bek Y Canturk F The comparison of effectiveness of alendronate and risedronate in osteoporosis treatment Turkiye Fiziksel Tip ve Rehabilitasyon Dergisi 2006 52 110 4"},{"issue":"6","key":"10.1002\/14651858.CD004523.pub4-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1111\/j.1742-1241.2008.01768.x","article-title":"Head-to-head comparison of risedronate vs. teriparatide on bone turnover markers in women with postmenopausal osteoporosis: a randomised trial","volume":"62","author":"Anastasilakis","year":"2008","journal-title":"International Journal of Clinical Practice"},{"issue":"6","key":"10.1002\/14651858.CD004523.pub4-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1007\/BF02850205","article-title":"Effects of alendronate and risedronate on bone mineral density and bone turnover markers in late postmenopausal women with osteoporosis","volume":"23","author":"Atmaca","year":"2006","journal-title":"Advances in Therapy"},{"issue":"2","key":"10.1002\/14651858.CD004523.pub4-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1002\/jbmr.2101","article-title":"Risedronate slows or partly reverses cortical and trabecular microarchitectural deterioration in postmenopausal women","volume":"29","author":"Bala","year":"2014","journal-title":"Journal of Bone and Mineral Research"},{"key":"10.1002\/14651858.CD004523.pub4-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s00223-002-2011-8","article-title":"The efficacy and tolerability of risedronate once a week for the treatment of postmenopausal osteoporosis","volume":"71","author":"Brown","year":"2002","journal-title":"Calcified Tissue International"},{"key":"10.1002\/14651858.CD004523.pub4-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1185\/030079904125003566","article-title":"Two-year efficacy and tolerability of risedronate once a week for the treatment of women with postmenopausal osteoporosis","volume":"20","author":"Harris","year":"2004","journal-title":"Current Medical Research and Opinion"},{"key":"10.1002\/14651858.CD004523.pub4-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1007\/PL00004152","article-title":"A 2-Year phase II study with 1-year of follow-up of risedronate (NE-58095) in postmenopausaloOsteoporosis","volume":"7","author":"Clemmesen","year":"1997","journal-title":"Osteoporosis International"},{"key":"10.1002\/14651858.CD004523.pub4-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.bone.2007.09.001","article-title":"Efficacy and safety of risedronate 150 mg once a month in the treatment of postmenopausal osteoporosis","volume":"42","author":"Delmas","year":"2008","journal-title":"Bone"},{"issue":"1","key":"10.1002\/14651858.CD004523.pub4-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1007\/s00198-012-2056-0","article-title":"Efficacy and safety of risedronate 150-mg once a month in the treatment of postmenopausal osteoporosis: 2-year data","volume":"24","author":"McClung","year":"2013","journal-title":"Osteoporosis International"},{"key":"10.1002\/14651858.CD004523.pub4-BIB0010|cit10","unstructured":"A Study of Monthly Risedronate for Osteoporosis ClinicalTrials.gov Database. Provided by Warner Chilcott."},{"key":"10.1002\/14651858.CD004523.pub4-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1007\/s00198-007-0531-9","article-title":"Monthly dosing of 75 mg risedronate on 2 consecutive days a month: efficacy and safety results","volume":"19","author":"Delmas","year":"2008","journal-title":"Osteoporosis International"},{"issue":"1","key":"10.1002\/14651858.CD004523.pub4-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/s00223-012-9668-4","article-title":"A novel monthly dosing regimen of risedronate for the treatment of postmenopausal osteoporosis: 2-year data","volume":"92","author":"McClung","year":"2013","journal-title":"Calcified Tissue International"},{"key":"10.1002\/14651858.CD004523.pub4-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1007\/s00198-005-0035-4","article-title":"Changes in the RANK ligand\/osteoprotegerin system are correlated to changes in bone mineral density in bisphosphonate-treated osteoporotic patients","volume":"17","author":"Dobnig","year":"2006","journal-title":"Osteoporosis International"},{"issue":"4","key":"10.1002\/14651858.CD004523.pub4-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1007\/s00774-009-0055-9","article-title":"The effect of risedronate treatment on serum cytokines in postmenopausal osteoporosis: a 6-month randomized and controlled study","volume":"27","author":"Dundar","year":"2009","journal-title":"Journal of Bone and Mineral Metabolism"},{"issue":"5","key":"10.1002\/14651858.CD004523.pub4-BIB0015|cit15","first-page":"1895","article-title":"Risedronate reverses bone loss in postmenopausal women with low bone mass: results from a multinational, double-blind, placebo-controlled trial. BMD-MN Study Group","volume":"85","author":"Fogelman","year":"2000","journal-title":"Journal of Clinical Endocrinology & Metabolism"},{"key":"10.1002\/14651858.CD004523.pub4-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1007\/s001980200135","article-title":"A Comparison of the effect of risedronate and etidronate on lumbar bone mineral density in Japanese patients with osteoporosis: a randomized controlled trial","volume":"13","author":"Fukunaga","year":"2002","journal-title":"Osteoporosis International"},{"issue":"Suppl 5","key":"10.1002\/14651858.CD004523.pub4-BIB0017|cit17","first-page":"S739","article-title":"Efficacy of bisphosphonates in the treatment of postmenopausal osteoporosis","volume":"22","author":"Galesanu","year":"2011","journal-title":"Osteoporosis International"},{"key":"10.1002\/14651858.CD004523.pub4-BIB0018|cit18","first-page":"841","article-title":"The efficacy and safety of weekly 35-mg risedronate dosing regimen for Chinese postmenopausal women with osteoporosis or osteopenia: 1-year data","volume":"36","author":"Gu","year":"2015","journal-title":"Chung Kuo Yao Li Hsueh Pao"},{"issue":"8","key":"10.1002\/14651858.CD004523.pub4-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.1007\/s00198-011-1856-y","article-title":"The effect of teriparatide compared with risedronate on reduction of back pain in postmenopausal women with osteoporotic vertebral fractures","volume":"23","author":"Hadji","year":"2012","journal-title":"Osteoporosis International"},{"key":"10.1002\/14651858.CD004523.pub4-BIB0020|cit20","unstructured":"Effect of teriparatide compared to risedronate on back pain in women with a spine fracture caused by osteoporosis ClinicalTrials.gov Database. Provided by Eli Lilly and Company."},{"issue":"14","key":"10.1002\/14651858.CD004523.pub4-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1001\/jama.282.14.1344","article-title":"Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group","volume":"282","author":"Harris","year":"1999","journal-title":"JAMA"},{"key":"10.1002\/14651858.CD004523.pub4-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1007\/s00223-004-0039-7","article-title":"Five years of treatment with risedronate and its effects on bone safety in women with postmenopausal osteoporosis","volume":"75","author":"Ste-Marie L","year":"2004","journal-title":"Calcified Tissue International"},{"issue":"5","key":"10.1002\/14651858.CD004523.pub4-BIB0023|cit23","first-page":"1890","article-title":"Effect of combined risedronate and hormone replacement therapies on bone mineral density in postmenopausal women","volume":"86","author":"Harris","year":"2001","journal-title":"Journal of Clinical Endocrinology & Metabolism"},{"key":"10.1002\/14651858.CD004523.pub4-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1080\/13697130500118126","article-title":"Risedronate prevents bone loss in early postmenopausal women: a prospective randomized, placebo-controlled trial","volume":"8","author":"Hooper","year":"2005","journal-title":"Climacteric"},{"issue":"5","key":"10.1002\/14651858.CD004523.pub4-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1185\/030079903125002009","article-title":"Comparison of change in bone resorption and bone mineral density with once-weekly alendronate and daily risedronate: a randomised, placebo-controlled study","volume":"19","author":"Hosking","year":"2003","journal-title":"Current Medical Research and Opinion"},{"key":"10.1002\/14651858.CD004523.pub4-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1007\/s00774-013-0490-5","article-title":"Effects of risedronate alone or combined with vitamin K2 on serum undercarboxylated osteocalcin and osteocalcin levels in postmenopausal osteoporosis","volume":"32","author":"Kasukawa","year":"2014","journal-title":"Journal of Bone and Mineral Metabolism"},{"key":"10.1002\/14651858.CD004523.pub4-BIB0027|cit27","unstructured":"Kato M Takaishi H H Kaneko K Matsumoto M Toyama Y Therapeutic effects of alfacalcidol, risedronate, and raloxifene on three-dimensional trabecular microarchitecture of cranial vertebral endplate in postmenopausal women: a prospective randomized trial using a multi-detector-raw CT imaging (SP28) Spine 2010 10"},{"key":"10.1002\/14651858.CD004523.pub4-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1007\/s00198-020-05463-4","article-title":"Efficacy of teriparatide compared with risedronate on FRAX\u00ae -defined major osteoporotic fractures: results of the VERO clinical trial","volume":"31","author":"Body","year":"2020","journal-title":"Osteoporosis International"},{"key":"10.1002\/14651858.CD004523.pub4-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/S0140-6736(17)32137-2","article-title":"Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial","volume":"391","author":"Kendler","year":"2018","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD004523.pub4-BIB0030|cit30","unstructured":"VERtebral fracture treatment comparisons in osteoporotic women (VERO) ClinicalTrials.gov Database, provided by Eli Lilly and Company."},{"issue":"2","key":"10.1002\/14651858.CD004523.pub4-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.bone.2004.10.014","article-title":"The efficacy and tolerability of risedronate on bone mineral density and bone turnover markers in osteoporotic Chinese women: a randomized placebo-controlled study","volume":"36","author":"Leung","year":"2005","journal-title":"Bone"},{"issue":"5","key":"10.1002\/14651858.CD004523.pub4-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1007\/BF02896007","article-title":"Efficacy and safety of risedronate sodium in treatment of postmenopausal osteoporosis","volume":"25","author":"Li","year":"2005","journal-title":"Journal of Huazhong University of Science and Technology"},{"issue":"1 Supplement","key":"10.1002\/14651858.CD004523.pub4-BIB0033|cit33","first-page":"S250","article-title":"Effect of osteoporosis medications on refracture and mortality following hip fracture surgery in postmenopausal women: a prospective randomized trial","volume":"28","author":"Lim S","year":"2017","journal-title":"Osteoporosis International"},{"issue":"5","key":"10.1002\/14651858.CD004523.pub4-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1056\/NEJM200102013440503","article-title":"Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group.","volume":"344","author":"McClung","year":"2001","journal-title":"New England Journal of Medicine"},{"issue":"1","key":"10.1002\/14651858.CD004523.pub4-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1007\/s00198-012-2175-7","article-title":"Treatment of postmenopausal osteoporosis with delayed-release risedronate 35 mg weekly for 2 years","volume":"24","author":"McClung","year":"2013","journal-title":"Osteoporosis International"},{"key":"10.1002\/14651858.CD004523.pub4-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/s00198-011-1791-y","article-title":"Efficacy and safety of a novel delayed-release risedronate 35 mg once-a-week tablet","volume":"23","author":"McClung","year":"2012","journal-title":"Osteoporosis International"},{"key":"10.1002\/14651858.CD004523.pub4-BIB0037|cit37","unstructured":"A study of a 35 mg delayed release Formulation of Risedronate for Osteoporosis ClinicalTrial.gov Database, provided by Warner Chilcott."},{"issue":"2","key":"10.1002\/14651858.CD004523.pub4-BIB0038|cit38","first-page":"396","article-title":"Risedronate increases bone mass in an early postmenopausal population: two years of treatment plus one year of follow-up","volume":"83","author":"Mortensen","year":"1998","journal-title":"Journal of Clinical Endocrinology & Metabolism"},{"key":"10.1002\/14651858.CD004523.pub4-BIB0039|cit39","first-page":"97","article-title":"Antiresorption therapy and reduction in fracture susceptibility in the osteoporotic elderly patient: open study","volume":"9","author":"Muscoso","year":"2004","journal-title":"European Review for Medical and Pharmacological Sciences"},{"key":"10.1002\/14651858.CD004523.pub4-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/s00223-013-9734-6","article-title":"Clinical efficacy on fracture risk and Safety of 0.5 mg or 1 mg\/month intravenous ibandronate versus 2.5 mg\/day oral risedronate in patients with primary osteoporosis","volume":"93","author":"Nakamura","year":"2013","journal-title":"Calcified Tissue International"},{"issue":"4","key":"10.1002\/14651858.CD004523.pub4-BIB0041|cit41","first-page":"543","article-title":"Effect of risedronate and strontium therapy on bone mineral density in postmenopausal osteoporosis","volume":"3","author":"Narula","year":"2012","journal-title":"International Journal of Research in Ayurveda and Pharmacy"},{"key":"10.1002\/14651858.CD004523.pub4-BIB0042|cit42","unstructured":"Sequential treatment of postmenopausal women with primary osteoporosis(FP-001-IM) (PEAK) clinicaltrials.gov\/ct2\/show\/NCT00365456"},{"key":"10.1002\/14651858.CD004523.pub4-BIB0043|cit43","unstructured":"A phase II\/III, double-blind, parallel group comparative study of oral administration of NE-58095 tablets clinicaltrials.gov\/ct2\/show\/NCT02063854"},{"issue":"8","key":"10.1002\/14651858.CD004523.pub4-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"E487","DOI":"10.1097\/BRS.0b013e31828826dd","article-title":"Comparison of teriparatide and bisphosphonate treatment to reduce pedicle screw loosening after lumbar spinal fusion surgery in postmenopausal women with osteoporosis from a bone quality perspective","volume":"38","author":"Ohtori","year":"2013","journal-title":"Spine"},{"issue":"12","key":"10.1002\/14651858.CD004523.pub4-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"2729","DOI":"10.1007\/s00198-014-2817-z","article-title":"Comparison of the effects of three oral bisphosphonate therapies on the peripheral skeleton in postmenopausal osteoporosis: the TRIO study","volume":"25","author":"Paggiosi M","year":"2014","journal-title":"Osteoporosis International"},{"issue":"1","key":"10.1002\/14651858.CD004523.pub4-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s001980050010","article-title":"Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group","volume":"11","author":"Reginster","year":"2000","journal-title":"Osteoporosis International"},{"issue":"2","key":"10.1002\/14651858.CD004523.pub4-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/S8756-3282(02)00946-8","article-title":"Long-term efficacy of risedronate: a 5-year placebo-controlled clinical experience","volume":"32","author":"Sorensen","year":"2003","journal-title":"Bone"},{"issue":"4","key":"10.1002\/14651858.CD004523.pub4-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1111\/j.1742-1241.2008.01704.x","article-title":"A comparison of the effect of alendronate and risedronate on bone mineral density in postmenopausal women with osteoporosis: 24-Month results from FACTS-International","volume":"62","author":"Reid","year":"2008","journal-title":"International Journal of Clinical Practice"},{"issue":"2","key":"10.1002\/14651858.CD004523.pub4-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"63","DOI":"10.2165\/00044011-200626020-00002","article-title":"Alendronic acid produces greater effects than risedronic acid on bone density and turnover in postmenopausal women with osteoporosis: Results of FACTS 1 -International","volume":"26","author":"Reid D","year":"2006","journal-title":"Clinical Drug Investigation"},{"issue":"7","key":"10.1002\/14651858.CD004523.pub4-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"2631","DOI":"10.1210\/jc.2005-2602","article-title":"Comparison of weekly treatment of postmenopausal osteoporosis with alendronate versus risedronate over two years","volume":"91","author":"Bonnick","year":"2006","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"issue":"1","key":"10.1002\/14651858.CD004523.pub4-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1359\/JBMR.040920","article-title":"Treatment with once-weekly alendronate 70 mg compared with once-weekly risedronate 35 mg in women with postmenopausal osteoporosis: a randomized double-blind study","volume":"20","author":"Rosen","year":"2005","journal-title":"Journal of Bone and Mineral Research"},{"key":"10.1002\/14651858.CD004523.pub4-BIB0052|cit52","unstructured":"Study to evaluate the safety and efficacy of denosumab and Actonel\u00ae in post menopausal women transitioned from alendronate therapy ClinicalTrials.gov Database, provided by Amgen."},{"key":"10.1002\/14651858.CD004523.pub4-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.bone.2013.10.006","article-title":"Denosumab compared with risedronate in postmenopausal women suboptimally adherent to alendronate therapy: efficacy and safety results from a randomized open-label study","volume":"58","author":"Ho","year":"2014","journal-title":"Bone"},{"key":"10.1002\/14651858.CD004523.pub4-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s00296-004-0544-z","article-title":"Comparison of the effects of alendronate and risedronate on bone mineral density and bone turnover markers in postmenopausal osteoporosis","volume":"26","author":"Sarioglu","year":"2006","journal-title":"Rheumatology international"},{"issue":"4","key":"10.1002\/14651858.CD004523.pub4-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1007\/s00774-016-0768-5","article-title":"Comparison of concurrent treatment with vitamin K 2 and risedronate compared with treatment with risedronate alone in patients with osteoporosis: Japanese Osteoporosis Intervention Trial-03","volume":"35","author":"Tanaka","year":"2017","journal-title":"Journal of Bone and Mineral Metabolism"},{"issue":"9","key":"10.1002\/14651858.CD004523.pub4-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1016\/j.clinthera.2007.09.017","article-title":"Effects of risedronate 5 mg\/d on bone mineral density and bone turnover markers in late-postmenopausal women with osteopenia: a multinational, 24-month, randomized, double-blind, placebo-controlled, parallel-group, phase III trial","volume":"29","author":"V\u00e4lim\u00e4ki","year":"2007","journal-title":"Clinical Therapeutics"},{"key":"10.1002\/14651858.CD004523.pub4-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1080\/08860220701260776","article-title":"The effect of alendronate, risedronate, and raloxifene on renal functions, based on the Cockcroft and Gault method, in postmenopausal women","volume":"29","author":"Yanik","year":"2007","journal-title":"Renal Failure"},{"issue":"1","key":"10.1002\/14651858.CD004523.pub4-BIB0058|cit58","first-page":"4","article-title":"The effect of raloxifene, alendronate and risedronate on serum lipid profile in postmenopausal women","volume":"54","author":"Yanik","year":"2008","journal-title":"Turkiye Fiziksel Tip ve Rehabilitasyon Dergisi"},{"key":"10.1002\/14651858.CD004523.pub4-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/BF03351502","article-title":"Tolerability of risedronate in postmenopausal women intolerant of alendronate","volume":"13","author":"Adachi","year":"2001","journal-title":"Aging - Clinical and Experimental Research"},{"key":"10.1002\/14651858.CD004523.pub4-BIB0060|cit60","first-page":"132","article-title":"The effect of risedronate treatment on bone turnover markers in patients with hip fracture","volume":"41","author":"Altintas","year":"2007","journal-title":"Acta orthopaedica et traumatologica turcica"},{"issue":"4","key":"10.1002\/14651858.CD004523.pub4-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1055\/s-2008-1046787","article-title":"Serum osteoprotegerin and RANKL are not specifically altered in women with postmenopausal osteoporosis treated with teriparatide or risedronate: a randomized, controlled trial","volume":"40","author":"Anastasilakis","year":"2008","journal-title":"Hormone and Metabolic Research"},{"issue":"9","key":"10.1002\/14651858.CD004523.pub4-BIB0062|cit62","first-page":"102","article-title":"Risedronate in the treatment and prevention of postmenopausal osteoporosis","volume":"35","year":"2001","journal-title":"Geneesmiddelenbulletin Medische Bulletin Hulpmiddelen"},{"key":"10.1002\/14651858.CD004523.pub4-BIB0063|cit63","first-page":"380","article-title":"Effects of risedronate on bone turnover markers in osteoporotic postmenopausal women: comparison of two protocols of treatment","volume":"87","author":"Bahlous","year":"2009","journal-title":"Tunisie Medicale"},{"key":"10.1002\/14651858.CD004523.pub4-BIB0064|cit64","first-page":"S58","article-title":"Risedronate slows or partly reverses microarchitecture deterioration depending on whether remodelling is perturbed or in steady state","volume":"24","author":"Bala","year":"2013","journal-title":"Osteoporosis International"},{"key":"10.1002\/14651858.CD004523.pub4-BIB0065|cit65","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1016\/j.bone.2003.12.013","article-title":"Risedronate preserves bone architecture in postmenopausal women with osteoporosis as measured by three-dimensional microcomputed tomography","volume":"34","author":"Borah","year":"2004","journal-title":"Bone"},{"key":"10.1002\/14651858.CD004523.pub4-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bone.2005.03.017","article-title":"The effect of risedronate on bone mineralization as measured by micro-computed tomography with synchrotron radiation: correlation to histomorphometric indices of turnover","volume":"37","author":"Borah","year":"2005","journal-title":"Bone"},{"key":"10.1002\/14651858.CD004523.pub4-BIB0067|cit67","doi-asserted-by":"crossref","unstructured":"Borah B Dufresne T Nurre J Phipps R Chmielewski P Wagner L Risedronate reduces intracortical porosity in women with osteoporosis Journal of Bone and Mineral Research 2010 25 41 7","DOI":"10.1359\/jbmr.090711"},{"key":"10.1002\/14651858.CD004523.pub4-BIB0068|cit68","doi-asserted-by":"crossref","first-page":"S61","DOI":"10.1016\/j.bone.2010.01.144","article-title":"Risedronate reduces intracortical porosity in postmenopausal women with osteoporosis as measured by a new 3D Micro-CT method","volume":"46","author":"Borah","year":"2010","journal-title":"Bone"},{"key":"10.1002\/14651858.CD004523.pub4-BIB0069|cit69","first-page":"1953","article-title":"Denosumab significantly increases bone mineral density and reduces bone turnover compared with monthly oral ibandronate and risedronate in postmenopausal women who remained at higher risk for fracture despite previous suboptimal treatment with an oral bisphosphonate","volume":"25","author":"Brown","year":"2014","journal-title":"Osteoporosis International"},{"key":"10.1002\/14651858.CD004523.pub4-BIB0070|cit70","doi-asserted-by":"crossref","first-page":"S203","DOI":"10.1016\/j.bone.2010.04.481","article-title":"Apparent bone mineral density at femoral neck in the monitoring the early effects of teriparatide","volume":"47","author":"Caffarelli","year":"2010","journal-title":"Bone"},{"key":"10.1002\/14651858.CD004523.pub4-BIB0071|cit71","doi-asserted-by":"crossref","first-page":"S220","DOI":"10.1016\/j.bone.2011.03.511","article-title":"Effects of intravenous zoledronic acid following subcutaneous teriparatide in postmenopausal osteoporosis","volume":"48","author":"Carlino","year":"2011","journal-title":"Bone"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD004523.pub4-BIB0072|cit72","first-page":"S100","article-title":"Risedronate reduces cortical structural decay during menopause, probably by reducing intracortical porosity","volume":"22","author":"Chapurlat","year":"2011","journal-title":"Osteoporosis International"},{"key":"10.1002\/14651858.CD004523.pub4-BIB0073|cit73","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/s00223-009-9294-y","article-title":"Comparison of monthly ibandronate versus weekly risedronate in preference, convenience, and bone turnover markers in Korean postmenopausal osteoporotic women","volume":"85","author":"Chung","year":"2009","journal-title":"Calcified Tissue International"},{"key":"10.1002\/14651858.CD004523.pub4-BIB0074|cit74","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1359\/jbmr.071031","article-title":"Risedronate reduces osteoclast precursors and cytokine production in postmenopausal osteoporotic women","volume":"23","author":"D'Amelio","year":"2008","journal-title":"Journal of Bone and Mineral Research"},{"key":"10.1002\/14651858.CD004523.pub4-BIB0075|cit75","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1080\/09513590801895617","article-title":"Effect of risedronate on biochemical marker of bone resorption in postmenopausal women with osteoporosis or osteopenia","volume":"24","author":"Dane","year":"2008","journal-title":"Gynecological Endocrinology"},{"key":"10.1002\/14651858.CD004523.pub4-BIB0076|cit76","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1210\/jc.2006-1526","article-title":"Effect of monitoring bone turnover markers on persistence with risedronate treatment of postmenopausal osteoporosis","volume":"92","author":"Delmas","year":"2007","journal-title":"Journal of clinical endocrinology and metabolism"},{"key":"10.1002\/14651858.CD004523.pub4-BIB0077|cit77","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1007\/s00223-002-2104-4","article-title":"Risedronate preserves bone architecture in early postmenopausal women in 1 year as measured by three-dimensional microcomputed tomography","volume":"73","author":"Dufresne","year":"2003","journal-title":"Calcified Tissue International"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD004523.pub4-BIB0078|cit78","doi-asserted-by":"crossref","first-page":"S53","DOI":"10.1016\/j.bone.2009.01.139","article-title":"Effects of risedronate on bone marrow adipocytes in postmenopausal women","volume":"44","author":"Duque","year":"2009","journal-title":"Bone"},{"key":"10.1002\/14651858.CD004523.pub4-BIB0079|cit79","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1007\/s00198-010-1353-8","article-title":"Effects of risedronate on bone marrow adipocytes in postmenopausal women","volume":"22","author":"Duque","year":"2011","journal-title":"Osteoporosis International"},{"key":"10.1002\/14651858.CD004523.pub4-BIB0080|cit80","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1359\/jbmr.060701","article-title":"Bone material properties in trabecular bone from human iliac crest biopsies after 3- and 5-year treatment with risedronate","volume":"21","author":"Durchschlag","year":"2006","journal-title":"Journal of Bone and Mineral Research"},{"key":"10.1002\/14651858.CD004523.pub4-BIB0081|cit81","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1359\/jbmr.2003.18.6.1051","article-title":"Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate","volume":"18","author":"Eastell","year":"2003","journal-title":"Journal of Bone and Mineral Research"},{"key":"10.1002\/14651858.CD004523.pub4-BIB0082|cit82","first-page":"S200","article-title":"Relationships between osteoporosis medication adherence, surrogate marker outcomes and non-vertebral fracture incidence","volume":"47","author":"Eastell","year":"2010","journal-title":"Bone"},{"key":"10.1002\/14651858.CD004523.pub4-BIB0083|cit83","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1002\/jbmr.342","article-title":"Bone turnover markers and bone mineral density response with risedronate therapy: relationship with fracture risk and patient adherence","volume":"26","author":"Eastell","year":"2011","journal-title":"Journal of Bone and Mineral Research"},{"issue":"S1","key":"10.1002\/14651858.CD004523.pub4-BIB0084|cit84","first-page":"Available at ht","article-title":"The effects of oral bisphosphonate therapy on the peripheral skeleton in postmenopausal osteoporosis: The trio study","volume":"28","author":"Eastell","year":"2013","journal-title":"Journal of Bone and Mineral Research"},{"issue":"5","key":"10.1002\/14651858.CD004523.pub4-BIB0085|cit85","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/S8756-3282(02)00869-4","article-title":"Effects of long-term risedronate on bone quality and bone turnover in women with postmenopausal osteoporosis","volume":"31","author":"Eriksen","year":"2002","journal-title":"Bone"},{"key":"10.1002\/14651858.CD004523.pub4-BIB0086|cit86","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1007\/s00774-009-0035-0","article-title":"Comparison of the analgesic effects of bisphosphonates: etidronate, alendronate and risedronate by electroalgometry utilizing the fall of skin impedance","volume":"27","author":"Fujita","year":"2009","journal-title":"Journal of Bone and Mineral Metabolism"},{"issue":"Supplement 1","key":"10.1002\/14651858.CD004523.pub4-BIB0087|cit87","first-page":"S22","article-title":"Teriparatide compared with risedronate and the risk of fractures in subgroups of postmenopausal women with severe osteoporosis: The VERO Trial","volume":"32","author":"Geusens","year":"2017","journal-title":"Journal of Bone and Mineral Research"},{"key":"10.1002\/14651858.CD004523.pub4-BIB0088|cit88","doi-asserted-by":"crossref","first-page":"83","DOI":"10.2165\/00002512-199813010-00008","article-title":"Risedronate","volume":"13","author":"Goa","year":"1998","journal-title":"Drugs and Aging"},{"key":"10.1002\/14651858.CD004523.pub4-BIB0089|cit89","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1007\/s00198-006-0157-3","article-title":"Teriparatide's effects on quantitative ultrasound parameters and bone density in women with established osteoporosis","volume":"17","author":"Gonnelli","year":"2006","journal-title":"Osteoporosis International"},{"key":"10.1002\/14651858.CD004523.pub4-BIB0090|cit90","doi-asserted-by":"crossref","first-page":"S204","DOI":"10.1016\/j.bone.2010.04.482","article-title":"The effect of 3 orally-administered bisphosphonates on the resorption of type I collagen in postmenopausal osteoporosis","volume":"47","author":"Gossiel","year":"2010","journal-title":"Bone"},{"key":"10.1002\/14651858.CD004523.pub4-BIB0091|cit91","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.bone.2016.08.010","article-title":"The effect of bisphosphonate treatment on osteoclast precursor cells in postmenopausal osteoporosis: The TRIO study","volume":"92","author":"Gossiel","year":"2016","journal-title":"Bone"},{"issue":"Supplement 2","key":"10.1002\/14651858.CD004523.pub4-BIB0092|cit92","first-page":"S621","article-title":"The effect of bisphosphonates on bone turnover and bone balance in postmenopausal women with osteoporosis: The T-score bone marker approach in the trio study","volume":"29","author":"Gossiel","year":"2018","journal-title":"Osteoporosis International"},{"key":"10.1002\/14651858.CD004523.pub4-BIB0093|cit93","doi-asserted-by":"crossref","first-page":"S228","DOI":"10.1016\/j.bone.2011.03.539","article-title":"Effect of teriparatide compared with risedronate on reduction of back pain and new vertebral fractures in postmenopausal women with osteoporotic vertebral fractures","volume":"48","author":"Hadji","year":"2011","journal-title":"Bone"},{"key":"10.1002\/14651858.CD004523.pub4-BIB0094|cit94","doi-asserted-by":"crossref","first-page":"S82","DOI":"10.1016\/j.bone.2011.03.108","article-title":"Effect of teriparatide compared with risedronate on back pain and incident vertebral fractures in postmenopausal women with osteoporotic vertebral fractures","volume":"48","author":"Hadji","year":"2011","journal-title":"Bone"},{"issue":"6","key":"10.1002\/14651858.CD004523.pub4-BIB0095|cit95","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1007\/s00223-014-9927-7","article-title":"Increased bone mineral density with monthly intravenous ibandronate contributes to fracture risk reduction in patients with primary osteoporosis: three-year analysis of the MOVER study","volume":"95","author":"Hagino","year":"2014","journal-title":"Calcified Tissue International"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD004523.pub4-BIB0096|cit96","first-page":"S404","article-title":"The effects of risedronate plus estrogen compared with estrogen alone in postmenopausal women","volume":"14","author":"Harris","year":"1999","journal-title":"Journal of Bone and Mineral Research"},{"issue":"1 Suppl 1","key":"10.1002\/14651858.CD004523.pub4-BIB0097|cit97","first-page":"S218","article-title":"Efficacy and safety of denosumab vs. Risedronate in postmenopausal women suboptimally adherent to alendronate: Results from a randomized open-label study","volume":"24","author":"Hofbauer","year":"2013","journal-title":"Osteoporosis International"},{"key":"10.1002\/14651858.CD004523.pub4-BIB0098|cit98","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1007\/s00774-014-0603-9","article-title":"Additive effect of elcatonin to risedronate for chronic back pain and quality of life in postmenopausal women with osteoporosis: a randomized controlled trial","volume":"33","author":"Hongo","year":"2015","journal-title":"Journal of Bone and Mineral Metabolism"},{"key":"10.1002\/14651858.CD004523.pub4-BIB0099|cit99","first-page":"80","article-title":"Risedronate prevents bone loss in early postmenopausal women","volume":"64","author":"Hooper","year":"1999","journal-title":"Calcified Tissue International"},{"key":"10.1002\/14651858.CD004523.pub4-BIB0100|cit100","doi-asserted-by":"crossref","first-page":"S428","DOI":"10.1016\/j.bone.2009.03.371","article-title":"One year of treatment with PTH (1-84) and the change in lumbar spine BMD in postmenopausal women with primary osteoporosis after pre-treatment with a bisphosphonate","volume":"44","author":"Hosking","year":"2009","journal-title":"Bone"},{"key":"10.1002\/14651858.CD004523.pub4-BIB0101|cit101","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1080\/13697130801959590","article-title":"Potential excessive suppression of bone turnover with long-term oral bisphosphonate therapy in postmenopausal osteoporotic patients","volume":"11","author":"Iizuka","year":"2008","journal-title":"Climacteric"},{"key":"10.1002\/14651858.CD004523.pub4-BIB0102|cit102","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1080\/13697130600652180","article-title":"Efficacy and acceptability of risedronate 5 mg daily compared with 35 mg once weekly for the treatment of postmenopausal osteoporosis","volume":"9","author":"Ilter","year":"2006","journal-title":"Climacteric"},{"issue":"6","key":"10.1002\/14651858.CD004523.pub4-BIB0103|cit103","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1007\/s00198-017-3966-7","article-title":"Health state utility values and patient-reported outcomes before and after vertebral and non-vertebral fractures in an osteoporosis clinical trial","volume":"28","author":"Imai","year":"2017","journal-title":"Osteoporosis International"},{"key":"10.1002\/14651858.CD004523.pub4-BIB0104|cit104","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s00774-015-0653-7","article-title":"Patient preference for monthly bisphosphonate versus weekly bisphosphonate in a cluster-randomized, open-label, crossover trial: Minodroate Alendronate\/Risedronate Trial in Osteoporosis (MARTO)","volume":"34","author":"Iwamoto","year":"2016","journal-title":"Journal of Bone and Mineral Metabolism"},{"key":"10.1002\/14651858.CD004523.pub4-BIB0105|cit105","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1007\/s00198-004-1698-y","article-title":"Risedronate decreases fracture risk in patients selected solely on the basis of prior vertebral fracture","volume":"16","author":"Kanis J","year":"2005","journal-title":"Osteoporosis International"},{"key":"10.1002\/14651858.CD004523.pub4-BIB0106|cit106","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.3109\/09513590.2011.579657","article-title":"The effect of risedronate treatment on serum osteoprotegerin and bone marker levels in postmenopausal women with osteoporosis","volume":"27","author":"Karadag-Saygi","year":"2011","journal-title":"Gynecological Endocrinology"},{"key":"10.1002\/14651858.CD004523.pub4-BIB0107|cit107","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1007\/s00198-009-0893-2","article-title":"Risedronate dosing before breakfast compared with dosing later in the day in women with postmenopausal osteoporosis","volume":"20","author":"Kendler","year":"2009","journal-title":"Osteoporosis International"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD004523.pub4-BIB0108|cit108","first-page":"S69","article-title":"Effects of 24 months treatment of teriparatide compared with risedronate on new fractures in postmenopausal women with severe osteoporosis: a randomized, double-dummy, clinical trial","volume":"28","author":"Kendler","year":"2017","journal-title":"Osteoporosis International"},{"key":"10.1002\/14651858.CD004523.pub4-BIB0109|cit109","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1007\/s00774-004-0509-z","article-title":"A comparison of incidences of vertebral fracture in Japanese patients with involutional osteoporosis treated with risedronate and etidronate: a randomized, double-masked trial","volume":"22","author":"Kushida","year":"2004","journal-title":"Journal of Bone and Mineral Metabolism"},{"key":"10.1002\/14651858.CD004523.pub4-BIB0110|cit110","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1053\/gast.2000.16517","article-title":"Endoscopic comparison of esophageal and gastroduodenal effects of risedronate and alendronate in postmenopausal women","volume":"119","author":"Lanza","year":"2000","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD004523.pub4-BIB0111|cit111","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1046\/j.1365-2036.2000.00887.x","article-title":"Placebo-controlled, randomized, evaluator-blinded endoscopy study of risedronate vs. aspirin in healthy postmenopausal women","volume":"14","author":"Lanza","year":"2000","journal-title":"Alimentary Pharmacology and Therapeutics"},{"issue":"1","key":"10.1002\/14651858.CD004523.pub4-BIB0112|cit112","first-page":"17","article-title":"Bisphosphonate therapy","volume":"313","author":"Licata","year":"1997","journal-title":"American Journal of the Medical Sciences"},{"key":"10.1002\/14651858.CD004523.pub4-BIB0113|cit113","doi-asserted-by":"crossref","first-page":"445","DOI":"10.2147\/CIA.S8200","article-title":"Reducing hip fracture risk with risedronate in elderly women with established osteoporosis","volume":"4","author":"Masud","year":"2009","journal-title":"Clinical Interventions in Aging"},{"issue":"3","key":"10.1002\/14651858.CD004523.pub4-BIB0114|cit114","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.archger.2004.10.001","article-title":"Interleukin-18 (IL-18) and matrix metalloproteinase-9 (MMP-9) in post-menopausal osteoporosis","volume":"40","author":"Maugeri","year":"2005","journal-title":"Archives of Gerontology and Geriatrics"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD004523.pub4-BIB0115|cit115","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1007\/BF02500566","article-title":"Risedronate treatment of postmenopausal women with low bone mass: preliminary data","volume":"6","author":"McClung","year":"1996","journal-title":"Osteoporosis International"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD004523.pub4-BIB0116|cit116","first-page":"111","article-title":"Risedronate increases bone mineral density at the hip, spine and radius in postmenopausal women with low bone mass","volume":"8","author":"McClung","year":"1998","journal-title":"Osteoporosis International"},{"issue":"S1","key":"10.1002\/14651858.CD004523.pub4-BIB0117|cit117","first-page":"S124","article-title":"Bmd response to a novel delayed-release risedronate 35 mg once-a-week formulation taken with or without breakfast: One year results","volume":"25","author":"McClung","year":"2010","journal-title":"Journal of Bone and Mineral Research"},{"key":"10.1002\/14651858.CD004523.pub4-BIB0118|cit118","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.jocd.2010.01.084","article-title":"BMD response to delayed-release risedronate 35 mg once-a-week formulation taken with or without breakfast (Poster Number 067)","volume":"13","author":"McClung","year":"2010","journal-title":"Journal of Clinical Densitometry"},{"key":"10.1002\/14651858.CD004523.pub4-BIB0119|cit119","doi-asserted-by":"crossref","unstructured":"McClung MR Zanchetta JR Benhamou CL Balske A Sarley J Recker RR Effect of a delayed-release risedronate 35 mg once-a-week formulation taken with or without breakfast on BMD Osteoporosis International 2010 S25","DOI":"10.1016\/j.jocd.2010.01.084"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD004523.pub4-BIB0120|cit120","first-page":"1","article-title":"Efficacy and safety of a novel delayed-release risedronate 35 mg once-a-week tablet","volume":"21","author":"McClung","year":"2011","journal-title":"Osteoporosis International"},{"key":"10.1002\/14651858.CD004523.pub4-BIB0121|cit121","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1007\/s00223-004-0286-7","article-title":"Seven years of treatment with risedronate in women with postmenopausal osteoporosis","volume":"75","author":"Mellstrom","year":"2004","journal-title":"Calcified Tissue International"},{"key":"10.1002\/14651858.CD004523.pub4-BIB0122|cit122","first-page":"S287","article-title":"Risedronate reduces hip fractures in patients with low femoral neck bone mineral density [abstract]","volume":"42","author":"Miller","year":"1999","journal-title":"Arthritis and Rheumatism"},{"issue":"5","key":"10.1002\/14651858.CD004523.pub4-BIB0123|cit123","doi-asserted-by":"crossref","first-page":"513-20","DOI":"10.1016\/S0002-9343(99)00062-5","article-title":"A randomized, double-blind comparison of risedronate and etidronate in the treatment of Paget\u2019s disease of bone. Paget\u2019s Risedronate\/Etidronate Study Group","volume":"106","author":"Miller","year":"1999","journal-title":"American Journal of Medicine"},{"issue":"1","key":"10.1002\/14651858.CD004523.pub4-BIB0124|cit124","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1007\/s11657-019-0561-x","article-title":"Serum 25-hydroxy-vitamin D and the risk of fractures in the teriparatide versus risedronate VERO clinical trial","volume":"14","author":"Minisola","year":"2019","journal-title":"Archives of Osteoporosis"},{"key":"10.1002\/14651858.CD004523.pub4-BIB0125|cit125","doi-asserted-by":"crossref","first-page":"E1464","DOI":"10.1097\/BRS.0b013e31826ca2a8","article-title":"Teriparatide accelerates lumbar posterolateral fusion in women with postmenopausal osteoporosis: prospective study","volume":"37","author":"Ohtori","year":"2012","journal-title":"Spine"},{"key":"10.1002\/14651858.CD004523.pub4-BIB0126|cit126","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.phrs.2008.03.010","article-title":"Raloxifene has favourable effects on metabolic parameters but has no effect on left ventricular function in postmenopausal women","volume":"57","author":"Oktem","year":"2008","journal-title":"Pharmacological Research"},{"key":"10.1002\/14651858.CD004523.pub4-BIB0127|cit127","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.rbo.2014.06.012","article-title":"Use of risedronate for consolidation and callus formation in Colles fractures in postmenopausal women: SOLID study","volume":"50","author":"Oliveira","year":"2015","journal-title":"Revista Brasileira de Ortopedia"},{"key":"10.1002\/14651858.CD004523.pub4-BIB0128|cit128","first-page":"67","article-title":"Compliance, persistence, and preference outcomes of postmenopausal osteoporotic women receiving a flexible or fixed regimen of daily risedronate: a multicenter, prospective, parallel group study","volume":"49","author":"Oral","year":"2015","journal-title":"Acta Orthopaedica et Traumatologica Turcica"},{"issue":"6 Supplement","key":"10.1002\/14651858.CD004523.pub4-BIB0129|cit129","first-page":"S692","article-title":"A comparison of the effects of three oral bisphosphonates on the peripheral skeleton in postmenopausal osteoporosis: The trio study","volume":"25","author":"Paggiosi","year":"2014","journal-title":"Osteoporosis International"},{"key":"10.1002\/14651858.CD004523.pub4-BIB0130|cit130","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1007\/s00198-005-1927-z","article-title":"Efficacy of risedronate administration in osteoporotic postmenopausal women affected by inflammatory bowel disease","volume":"16","author":"Palomba","year":"2005","journal-title":"Osteoporosis International"},{"key":"10.1002\/14651858.CD004523.pub4-BIB0131|cit131","doi-asserted-by":"crossref","first-page":"695","DOI":"10.3945\/ajcn.114.093906","article-title":"Impact of equol-producing capacity and soy-isoflavone profiles of supplements on bone calcium retention in postmenopausal women: a randomized crossover trial","volume":"102","author":"Pawlowski","year":"2015","journal-title":"American Journal of Clinical Nutrition"},{"key":"10.1002\/14651858.CD004523.pub4-BIB0132|cit132","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.mayocp.2012.08.019","article-title":"Effects of bisphosphonate treatment on circulating osteogenic endothelial progenitor cells in postmenopausal women","volume":"88","author":"Peris","year":"2013","journal-title":"Mayo Clinic Proceedings"},{"key":"10.1002\/14651858.CD004523.pub4-BIB0133|cit133","doi-asserted-by":"crossref","first-page":"3079","DOI":"10.1185\/030079907X242665","article-title":"Monthly dosing with risedronate 50 mg on three consecutive days a month compared with daily dosing with risedronate 5 mg: a 6-month pilot study","volume":"23","author":"Racewicz","year":"2007","journal-title":"Current Medical Research and Opinion"},{"key":"10.1002\/14651858.CD004523.pub4-BIB0134|cit134","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1007\/s00223-011-9482-4","article-title":"Randomized trial of alendronate plus vitamin D3 versus standard care in osteoporotic postmenopausal women with vitamin D insufficiency","volume":"88","author":"Ralston","year":"2011","journal-title":"Calcified Tissue International"},{"issue":"S1","key":"10.1002\/14651858.CD004523.pub4-BIB0135|cit135","first-page":"S361","article-title":"Bone safety of a novel delayed-release risedronate 35 mg once-a-week assessed by bone histology and histomorphometry","volume":"26","author":"Recker","year":"2011","journal-title":"Journal of Bone and Mineral Research"},{"key":"10.1002\/14651858.CD004523.pub4-BIB0136|cit136","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/s00198-014-2850-y","article-title":"Bone safety with risedronate: histomorphometric studies at different dose levels and exposure","volume":"26","author":"Recker","year":"2015","journal-title":"Osteoporosis International"},{"issue":"2","key":"10.1002\/14651858.CD004523.pub4-BIB0137|cit137","first-page":"121","article-title":"Risedronate increases bone mineral density and reduces the vertebral fracture incidence in postmenopausal women","volume":"19","author":"Reginster","year":"2001","journal-title":"Clinical and Experimental Rheumatology"},{"issue":"49","key":"10.1002\/14651858.CD004523.pub4-BIB0138|cit138","doi-asserted-by":"crossref","first-page":"34967","DOI":"10.1074\/jbc.274.49.34967","article-title":"Bisphosphonates act directly on the osteoclast to induce caspase cleavage of mst1 kinase during apoptosis. A link between inhibition of the mevalonate pathway and regulation of an apoptosis-promoting kinase","volume":"274","author":"Reszka","year":"1999","journal-title":"Journal of Biological Chemistry"},{"key":"10.1002\/14651858.CD004523.pub4-BIB0139|cit139","first-page":"S163","article-title":"Risedronate increases bone mineral density and is well tolerated in postmenopausal women with low bone mineral density","volume":"14","author":"Ribot","year":"1999","journal-title":"Journal of Bone and Mineral Research"},{"key":"10.1002\/14651858.CD004523.pub4-BIB0140|cit140","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1185\/030079903125003125","article-title":"Efficacy of risedronate on clinical vertebral fractures within six months","volume":"20","author":"Roux","year":"2004","journal-title":"Current Medical Research and Opinion"},{"key":"10.1002\/14651858.CD004523.pub4-BIB0141|cit141","doi-asserted-by":"crossref","first-page":"A306","DOI":"10.1136\/annrheumdis-2013-eular.946","article-title":"Denosumab versus risedronate: efficacy and safety in postmenopausal women suboptimally adherent to alendronate therapy in a randomized open-label study","volume":"72","author":"Roux","year":"2013","journal-title":"Annals of Rheumatic Diseases"},{"key":"10.1002\/14651858.CD004523.pub4-BIB0142|cit142","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1185\/030079904X16768","article-title":"Response to therapy with once-weekly alendronate 70 mg compared to once-weekly risedronate 35 mg in the treatment of postmenopausal osteoporosis","volume":"20","author":"Sebba","year":"2004","journal-title":"Current Medical Research and Opinion"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD004523.pub4-BIB0143|cit143","first-page":"S9","article-title":"Risedronate reduces micro-structural deterioration of cortical bone accompanying menopause","volume":"21","author":"Seeman","year":"2010","journal-title":"Osteoporosis International"},{"key":"10.1002\/14651858.CD004523.pub4-BIB0144|cit144","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1359\/JBMR.0301231","article-title":"Relationship between pretreatment bone resorption and vertebral fracture incidence in postmenopausal osteoporotic women treated with risedronate","volume":"19","author":"Seibel","year":"2004","journal-title":"Journal of Bone and Mineral Research"},{"key":"10.1002\/14651858.CD004523.pub4-BIB0145|cit145","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s00198-002-1369-9","article-title":"A double-blind dose-ranging study of risedronate in Japanese patients with osteoporosis (a study by the Risedronate Late Phase II Research Group)","volume":"14","author":"Shiraki","year":"2003","journal-title":"Osteoporosis International"},{"key":"10.1002\/14651858.CD004523.pub4-BIB0146|cit146","first-page":"259","article-title":"Bisphosphonates in the treatment of disorders of mineral metabolism","volume":"6","author":"Singer","year":"1995","journal-title":"Therapeutic Advances in Endocrinology and Metabolism"},{"key":"10.1002\/14651858.CD004523.pub4-BIB0147|cit147","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.clinthera.2009.02.012","article-title":"Comparison of the effects of once-monthly versus once-daily risedronate in postmenopausal osteoporosis: a phase II, 6-month, multicenter, randomized, double-blind, active-controlled, dose-ranging study","volume":"31","author":"Ste-Marie","year":"2009","journal-title":"Clinical Therapeutics"},{"key":"10.1002\/14651858.CD004523.pub4-BIB0148|cit148","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1089\/jwh.2009.1438","article-title":"Response to oral bisphosphonates in subgroups of younger and older postmenopausal women","volume":"19","author":"Stovall","year":"2010","journal-title":"Journal of Women's Health"},{"key":"10.1002\/14651858.CD004523.pub4-BIB0149|cit149","doi-asserted-by":"crossref","first-page":"42","DOI":"10.3810\/pgm.2009.07.2028","article-title":"Once-a-month risedronate in postmenopausal osteoporosis","volume":"121","author":"Sunyecz","year":"2009","journal-title":"Postgraduate Medicine"},{"key":"10.1002\/14651858.CD004523.pub4-BIB0150|cit150","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1007\/s00774-006-0739-3","article-title":"Changes in bone resorption markers among Japanese patients with postmenopausal osteoporosis treated with alendronate and risedronate","volume":"25","author":"Takada","year":"2007","journal-title":"Journal of Bone and Mineral Metabolism"},{"key":"10.1002\/14651858.CD004523.pub4-BIB0151|cit151","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1007\/s00774-013-0491-4","article-title":"Design of a randomized clinical trial of concurrent treatment with vitamin K2 and risedronate compared to risedronate alone in osteoporotic patients: Japanese Osteoporosis Intervention Trial-03 (JOINT-03)","volume":"32","author":"Tanaka","year":"2014","journal-title":"Journal of Bone and Mineral Metabolism"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD004523.pub4-BIB0152|cit152","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1007\/BF02500585","article-title":"A three-year double-blind placebo-controlled study of risedronate in postmenopausal osteoporosis","volume":"6","author":"Taquet","year":"1996","journal-title":"Osteoporosis International"},{"key":"10.1002\/14651858.CD004523.pub4-BIB0153|cit153","first-page":"1965","article-title":"14 Day endoscopy study comparing risedronate and alendronate in postmenopausal women stratified by Helicobacter pylori status","volume":"29","author":"Thomson","year":"2002","journal-title":"Journal of Rheumatology"},{"issue":"2","key":"10.1002\/14651858.CD004523.pub4-BIB0154|cit154","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/S0889-8529(05)70014-1","article-title":"Treatment of osteoporosis with bisphosphonates","volume":"27","author":"Watts","year":"1998","journal-title":"Endocrinology and Metabolism Clinics of North America"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD004523.pub4-BIB0155|cit155","first-page":"S136","article-title":"Risedronate reduces vertebral fracture risk after the first year of treatment in postmenopausal women with established osteoporosis","volume":"14","author":"Watts","year":"1999","journal-title":"Journal of Bone and Mineral Research"},{"key":"10.1002\/14651858.CD004523.pub4-BIB0156|cit156","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1210\/jc.2002-020400","article-title":"Risedronate prevents new vertebral fractures in postmenopausal women at high risk","volume":"88","author":"Watts","year":"2003","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"10.1002\/14651858.CD004523.pub4-BIB0157|cit157","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s00198-007-0460-7","article-title":"Fracture risk remains reduced one year after discontinuation of risedronate","volume":"19","author":"Watts","year":"2008","journal-title":"Osteoporosis International"},{"key":"10.1002\/14651858.CD004523.pub4-BIB0158|cit158","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/S8756-3282(00)00410-5","article-title":"Effect of high doses of oral risedronate (20 mg\/day) on serum parathyroid hormone levels and urinary collagen cross-link excretion in postmenopausal women with spinal osteoporosis","volume":"28","author":"Zegels","year":"2001","journal-title":"Bone"},{"issue":"Suppl 10","key":"10.1002\/14651858.CD004523.pub4-BIB0159|cit159","first-page":"Abstract Number","article-title":"Teriparatide compared with risedronate and the risk of clinical vertebral fractures: 2-year results of a randomized, double-dummy clinical trial","volume":"69","author":"Zerbini CA Geusens","year":"2017","journal-title":"Arthritis and Rheumatology"},{"issue":"7","key":"10.1002\/14651858.CD004523.pub4-BIB0160|cit160","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1359\/jbmr.060401","article-title":"Effects of 3- and 5-year treatment with risedronate on bone mineralization density distribution in triple biopsies of the iliac crest in postmenopausal women","volume":"21","author":"Zoehrer","year":"2006","journal-title":"Journal of Bone and Mineral Research"},{"key":"10.1002\/14651858.CD004523.pub4-BIB0161|cit161","unstructured":"Benhamou CL Seefried L Agodoa I Vanden Bergh JP Prince RL Josse RG Treatment satisfaction in postmenopausal women suboptimally adherent to alendronate who transitioned to denosumab vs risedronate Osteoporosis International 2013 24 1 Suppl 1 S159 60"},{"key":"10.1002\/14651858.CD004523.pub4-BIB0162|cit162","doi-asserted-by":"crossref","unstructured":"Bilek LD Waltman NL Lappe JM Kupzyk KA Mack LR Cullen DM Protocol for a randomized controlled trial to compare bone-loading exercises with risedronate for preventing bone loss in osteopenic postmenopausal women BMC Womens Health 2016 16 1 59","DOI":"10.1186\/s12905-016-0339-x"},{"issue":"1 (Special)","key":"10.1002\/14651858.CD004523.pub4-BIB0163|cit163","first-page":"495","article-title":"Efficacy of combined medication of risedronate sodium and selective estrogen receptor modulator on the postmenopausal osteoporosis","volume":"33","author":"Deng","year":"2000","journal-title":"Pakistan Journal of Pharmaceutical Sciences"},{"key":"10.1002\/14651858.CD004523.pub4-BIB0164|cit164","doi-asserted-by":"crossref","unstructured":"Felsenberg D Charpulat R Cheung AM LaRoche M Morris E Seeman E Longitudinal in vivo micro-CT assessment in osteopenic women demonstrated that risedronate reduced the deterioration of cortical bone Bone 2010 47 Supplement 1 S35","DOI":"10.1016\/j.bone.2010.04.058"},{"key":"10.1002\/14651858.CD004523.pub4-BIB0165|cit165","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.bone.2013.10.017","article-title":"Efficacy, tolerability and safety of once-monthly administration of 75 mg risedronate in Japanese patients with involutional osteoporosis: A comparison with a 2.5 mg once-daily dosage regimen","volume":"59","author":"Kishimoto","year":"2014","journal-title":"Bone"},{"key":"10.1002\/14651858.CD004523.pub4-BIB0166|cit166","doi-asserted-by":"crossref","unstructured":"Ia Vilari\u00f1o S Vilarino C Schwartz A Contreras Ortiz O Dotto J Comparison of different treatments on postmenopausal patients (POSTM) Maturitas 2009 S95","DOI":"10.1016\/S0378-5122(09)70379-2"},{"key":"10.1002\/14651858.CD004523.pub4-BIB0167|cit167","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.maturitas.2019.04.098","article-title":"Effects of risedronate versus menopausal hormone therapy on bone mineral density in postmenopausal Korean women with hip fracture: a randomized, open-label trial","volume":"124","author":"Lim","journal-title":"Maturitas"},{"key":"10.1002\/14651858.CD004523.pub4-BIB0168|cit168","unstructured":"Matsuzaki K Kaneko H Kato M Hikata T Nango N Efficacy of osteoporotic agents in trabecular microstructure (SU0313) Journal of Bone and Mineral Research 2012 27 S1 S304"},{"key":"10.1002\/14651858.CD004523.pub4-BIB0169|cit169","unstructured":"Risedronate in osteopenic postmenopausal women (OSMAUSE) clinicaltrials.gov\/ct2\/show\/NCT00345644"},{"key":"10.1002\/14651858.CD004523.pub4-BIB0170|cit170","unstructured":"Study of the effect of once a week risedronate on the microstructure of tibia and radius using a new scanning method clinicaltrials.gov\/ct2\/show\/NCT00386360"},{"key":"10.1002\/14651858.CD004523.pub4-BIB0171|cit171","unstructured":"Risedronate in thepPrevention of osteoporosis in postmenopausal women clinicaltrials.gov\/ct2\/show\/NCT00402441"},{"key":"10.1002\/14651858.CD004523.pub4-BIB0172|cit172","unstructured":"Risedronate vs raloxifene in hormone replacement therapy discontinuation clinicaltrials.gov\/ct2\/show\/NCT00790101"},{"key":"10.1002\/14651858.CD004523.pub4-BIB0173|cit173","unstructured":"To evaluate the efficacy and the safety of monthly versus weekly oral risedronate with vitamin D in compliance, improvement of vitamin D and BMD in Korean postmenopausal osteoporotic women clinicaltrials.gov\/ct2\/show\/NCT01904110"},{"key":"10.1002\/14651858.CD004523.pub4-BIB0174|cit174","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/j.lfs.2010.10.006","article-title":"Beneficial effect of risedronate on arterial thickening and stiffening with a reciprocal relationship to its effect on bone mass in female osteoporosis patients: a longitudinal study","volume":"87","author":"Okamoto","year":"2010","journal-title":"Life Sciences"},{"key":"10.1002\/14651858.CD004523.pub4-BIB0175|cit175","unstructured":"Pastore R Bultrini A DiGiacinto P Cannuccia A Frontoni S Sequentialtherapy in severe osteoporosis Osteoporosis International 2014 S254"},{"key":"10.1002\/14651858.CD004523.pub4-BIB0176|cit176","unstructured":"Seeman E Borah B Chapurlat R Felsenberg D Darbie L Rizzoli R Risedronate reduces deterioration of cortical bone microarchitecture accompanying menopause Journal of Bone and Mineral Research 2010 S32"},{"key":"10.1002\/14651858.CD004523.pub4-BIB0177|cit177","unstructured":"Efficacy of bazedoxifene on vascular endothelial function in postmenopausal women with osteoporosis ictrptest.azurewebsites.net\/Trial2.aspx?TrialID=JPRN-UMIN000010017"},{"key":"10.1002\/14651858.CD004523.pub4-BIB0178|cit178","doi-asserted-by":"crossref","first-page":"110","DOI":"10.4274\/tod.78941","article-title":"Evalution the effects of raloxifene and risedronate on serum biochemical markers","volume":"20","author":"Yeter","year":"2014","journal-title":"Turkish Journal of Osteoporosis"},{"key":"10.1002\/14651858.CD004523.pub4-BIB0179|cit179","doi-asserted-by":"crossref","first-page":"85","DOI":"10.3233\/BMR-2005-183-405","article-title":"Comparison of the effects of alendronate, risedronate and calcitonin treatment in postmenopausal osteoporosis","volume":"18","author":"Yildirim","year":"2005","journal-title":"Journal of Back and Musculoskeletal Rehabilitation"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD004523.pub4-BIB0180|cit180","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4158\/GL-2020-0524SUPPL","article-title":"American Association of Clinical Endocrinologists\/American College of Endocrinology clinical practice guidelines for the diagnosis and treatment of postmenopausal osteoporosis-2020 update","volume":"26","author":"Camacho","year":"2020","journal-title":"Endocrine Practice"},{"issue":"5","key":"10.1002\/14651858.CD004523.pub4-BIB0181|cit181","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1210\/jc.2019-00192","article-title":"Efficacy of pharmacological therapies for the prevention of fractures in postmenopausal women: a network meta-analysis","volume":"104","author":"Barrionuevo","year":"2019","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"issue":"7","key":"10.1002\/14651858.CD004523.pub4-BIB0182|cit182","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1007\/s001980170072","article-title":"An assessment tool for predicting fracture risk in postmenopausal women","volume":"12","author":"Black","year":"2001","journal-title":"Osteoporos International"},{"key":"10.1002\/14651858.CD004523.pub4-BIB0183|cit183","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1007\/s00198-020-05463-4","article-title":"Efficacy of teriparatide compared with risedronate on FRAX\u00ae -defined major osteoporotic fractures: results of the VERO clinical trial.","volume":"31","author":"Body","year":"2020","journal-title":"Osteoporosis International"},{"issue":"10 Suppl","key":"10.1002\/14651858.CD004523.pub4-BIB0184|cit184","first-page":"S1","article-title":"2002 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada","volume":"167","author":"Brown","year":"2002","journal-title":"Canadian Medical Association Journal"},{"issue":"7","key":"10.1002\/14651858.CD004523.pub4-BIB0185|cit185","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1007\/s001980070075","article-title":"Risk of mortality following clinical fractures","volume":"11","author":"Cauley","year":"2000","journal-title":"Osteoporosis International"},{"issue":"7","key":"10.1002\/14651858.CD004523.pub4-BIB0186|cit186","doi-asserted-by":"crossref","first-page":"364","DOI":"10.11622\/smedj.2019028","article-title":"Efficacy and safety of denosumab compared to bisphosphonates in improving bone strength in postmenopausal osteoporosis: a systematic review","volume":"60","author":"Chandran","year":"2019","journal-title":"Singapore Medical Journal"},{"issue":"10","key":"10.1002\/14651858.CD004523.pub4-BIB0187|cit187","doi-asserted-by":"crossref","first-page":"711","DOI":"10.7326\/M14-0317","article-title":"Comparative effectiveness of pharmacologic treatments to prevent fractures: an updated systematic review","volume":"161","author":"Crandall","year":"2014","journal-title":"Annals of Internal Medicine"},{"issue":"4","key":"10.1002\/14651858.CD004523.pub4-BIB0188|cit188","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1210\/er.2001-3002","article-title":"Meta-analyses of therapies for postmenopausal osteoporosis. III. Meta-analysis of risedronate for the treatment of postmenopausal osteoporosis","volume":"23","author":"Cranney","year":"2002","journal-title":"Endocrine Reviews"},{"issue":"11","key":"10.1002\/14651858.CD004523.pub4-BIB0189|cit189","doi-asserted-by":"crossref","first-page":"2445","DOI":"10.1001\/archinte.1989.00390110045010","article-title":"Lifetime risks of hip, Colles', or vertebral fracture and coronary heart disease among white postmenopausal women","volume":"149","author":"Cummings","year":"1989","journal-title":"Archives of Internal Medicine"},{"key":"10.1002\/14651858.CD004523.pub4-BIB0190|cit190","unstructured":"Deeks JJ Higgins JP Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al (editors) Cochrane Handbook for Systematic Reviews of Interventions version 6.0 The Cochrane Collaboration"},{"issue":"3","key":"10.1002\/14651858.CD004523.pub4-BIB0191|cit191","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1037\/h0087425","article-title":"The p-value fallacy and how to avoid it","volume":"57","author":"Dixon","year":"2003","journal-title":"Canadian Journal of Experimental Psychology"},{"issue":"1","key":"10.1002\/14651858.CD004523.pub4-BIB0192|cit192","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1007\/s001980170152","article-title":"Lifetime and five-year age-specific risks of first and subsequent osteoporotic fractures in postmenopausal women","volume":"12","author":"Doherty","year":"2001","journal-title":"Osteoporosis International"},{"issue":"5","key":"10.1002\/14651858.CD004523.pub4-BIB0193|cit193","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1210\/jc.2019-00221","article-title":"Pharmacological Management of osteoporosis in postmenopausal women: an Endocrine Society* Clinical Practice Guideline","volume":"104","author":"Eastell","year":"2019","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"issue":"4","key":"10.1002\/14651858.CD004523.pub4-BIB0194|cit194","doi-asserted-by":"crossref","first-page":"297","DOI":"10.2106\/JBJS.K.01181","article-title":"Bisphosphonates and nonhealing femoral fractures: analysis of the FDA Adverse Event Reporting System (FAERS) and international safety efforts: a systematic review from the Research on Adverse Drug Events And Reports (RADAR) project","volume":"95","author":"Edwards","year":"2013","journal-title":"Journal of Bone and Jjoint Surgery"},{"issue":"4","key":"10.1002\/14651858.CD004523.pub4-BIB0195|cit195","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.jval.2014.01.008","article-title":"Bazedoxifene versus oral bisphosphonates for the prevention of nonvertebral fractures in postmenopausal women with osteoporosis at higher risk of fracture: a network meta-analysis","volume":"17","author":"Ellis","year":"2014","journal-title":"Value in Health"},{"key":"10.1002\/14651858.CD004523.pub4-BIB0196|cit196","unstructured":"Reporting the effects of an intervention in EPOC review EPOC Resources for review authors 2018 https:\/\/epoc.cochrane.org\/resources\/epoc-resources-review-authors (accessed 27 October 2020)"},{"key":"10.1002\/14651858.CD004523.pub4-BIB0197|cit197","unstructured":"FDA Drug Approval Package-Actonel\u00ae Risedronate Sodium Tablets Application No.: 20-835\/S1, S2, S3 & S4 2000 https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2000\/20835S001_Actonel.cfm"},{"issue":"7","key":"10.1002\/14651858.CD004523.pub4-BIB0198|cit198","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1359\/JBMR.050314","article-title":"What proportion of incident radiographic vertebral deformities is clinically diagnosed and vice versa?","volume":"20","author":"Fink","year":"2005","journal-title":"Journal of Bone and Mineral Research"},{"key":"10.1002\/14651858.CD004523.pub4-BIB0199|cit199","unstructured":"GRADEpro GDT: GRADEpro Guideline Development Tool [Software] McMaster University . 2015 (developed by Evidence Prime, Inc.). Available from gradepro.org"},{"issue":"4","key":"10.1002\/14651858.CD004523.pub4-BIB0200|cit200","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1385\/JCD:4:4:373","article-title":"Instant vertebral assessment: a noninvasive dual X-ray absorptiometry technique to avoid misclassification and clinical mismanagement of osteoporosis","volume":"4","author":"Greenspan","year":"2001","journal-title":"Journal of Clinical Densitometry"},{"key":"10.1002\/14651858.CD004523.pub4-BIB0201|cit201","unstructured":"Health Canada Product Monograph-Actonel\u00ae Risedronate Sodium tablets 5 mg, 30 mg, 35 mg, 150 mg, and delayed release 35 mg 2017 https:\/\/pdf.hres.ca\/dpd_pm\/00040591.PDF"},{"key":"10.1002\/14651858.CD004523.pub4-BIB0202|cit202","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1111\/j.1365-2249.2005.02665.x","article-title":"The bisphosphonate acute phase response: rapid and copious production of proinflammatory cytokines by peripheral bloodgdT cells in response to aminobisphosphonates is inhibited by statins","volume":"139","author":"Hewitt","year":"2005","journal-title":"Clinical and Experimental Immunology"},{"key":"10.1002\/14651858.CD004523.pub4-BIB0203|cit203","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions version 5.2.0 (updated June 2017)","author":"Higgins","year":"2017"},{"key":"10.1002\/14651858.CD004523.pub4-BIB0204|cit204","doi-asserted-by":"crossref","unstructured":"Higgins JP Thomas J Chandler J Cumpston M Li T Page MJ Cochrane Handbook for Systematic Reviews of Interventions\u00a0version 6.1\u00a0(updated September 2020) Cochrane","DOI":"10.1002\/9781119536604"},{"key":"10.1002\/14651858.CD004523.pub4-BIB0205|cit205","unstructured":"Higgins JP Lasserson T Chandler J Tovey D Thomas J Flemyng E Methodological Expectations of Cochrane Intervention Reviews Cochrane: London,\u00a0version February 2021"},{"issue":"11","key":"10.1002\/14651858.CD004523.pub4-BIB0206|cit206","first-page":"1426","article-title":"Do bisphosphonates reduce the risk of osteoporotic fractures? An evaluation of the evidence to date","volume":"166","author":"Hodsman","year":"2002","journal-title":"Canadian Medical Association Journal"},{"key":"10.1002\/14651858.CD004523.pub4-BIB0207|cit207","doi-asserted-by":"crossref","first-page":"209. doi: 10.11","DOI":"10.1186\/1471-2474-12-209","article-title":"The relative efficacy of nine osteoporosis medications for reducing the rate of fractures in post-menopausal women","volume":"12","author":"Hopkins","year":"2011","journal-title":"BMC Musculoskeletal Disorders"},{"issue":"4","key":"10.1002\/14651858.CD004523.pub4-BIB0208|cit208","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.semarthrit.2010.06.001","article-title":"The efficacy of bisphosphonates in the prevention of vertebral, hip, and nonvertebral-non hip fractures in osteoporosis: a network meta-analysis","volume":"40","author":"Jansen","year":"2011","journal-title":"Seminars in Arthritis and Rheumatism"},{"key":"10.1002\/14651858.CD004523.pub4-BIB0209|cit209","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1007\/s00198-006-0172-4","article-title":"An estimate of the worldwide prevalence and disability associated with osteoporotic fractures","volume":"17","author":"Johnell","year":"2006","journal-title":"Osteoporosis International"},{"issue":"1-2","key":"10.1002\/14651858.CD004523.pub4-BIB0210|cit210","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1007\/s11657-013-0144-1","article-title":"SCOPE: a scorecard for osteoporosis in Europe","volume":"8","author":"Kanis","year":"2013","journal-title":"Archives of Osteoporosis"},{"issue":"1","key":"10.1002\/14651858.CD004523.pub4-BIB0211|cit211","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s12603-015-0652-3","article-title":"Epidemiology and postoperative outcomes of atypical femoral fractures in older adults: a systematic review","volume":"21","author":"Khow","year":"2017","journal-title":"Journal of Nutrition, Health and Aging"},{"issue":"9","key":"10.1002\/14651858.CD004523.pub4-BIB0212|cit212","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1359\/jbmr.090319","article-title":"Repeat low-trauma fractures occur frequently among men and women who have osteopenic BMD","volume":"24","author":"Langsetmo","year":"2009","journal-title":"Journal of Bone and Mineral Research"},{"issue":"3","key":"10.1002\/14651858.CD004523.pub4-BIB0213|cit213","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1007\/s00198-013-2575-3","article-title":"Risk of osteonecrosis in patients taking bisphosphonates for prevention of osteoporosis: a systematic review and meta-analysis","volume":"25","author":"Lee","year":"2014","journal-title":"Osteoporosis International"},{"issue":"6","key":"10.1002\/14651858.CD004523.pub4-BIB0214|cit214","doi-asserted-by":"crossref","first-page":"4469","DOI":"10.1002\/jcb.26550","article-title":"A network meta-analysis on the short-term efficacy and adverse events of different anti-osteoporosis for the treatment of postmenopausal osteoporosis","volume":"119","author":"Liu","year":"2018","journal-title":"Journal of Cell Biochemistry"},{"key":"10.1002\/14651858.CD004523.pub4-BIB0215|cit215","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.joms.2006.10.061","article-title":"Nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in Australia","volume":"65","author":"Mavrokokki","year":"2007","journal-title":"Journal of Oral Maxillofacial Surgery"},{"key":"10.1002\/14651858.CD004523.pub4-BIB0216|cit216","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.jclinepi.2016.01.021","article-title":"PRESS Peer Review of Electronic Search Strategies: 2015 guideline statement","volume":"75","author":"McGowan","year":"2016","journal-title":"Journal of Clinical Epidemiology"},{"issue":"12","key":"10.1002\/14651858.CD004523.pub4-BIB0217|cit217","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1001\/archinternmed.2012.1796","article-title":"Increasing occurrence of atypical femoral fractures associated with bisphosphonate use","volume":"172","author":"Meier","year":"2012","journal-title":"Archives of Internal Medicine"},{"issue":"5","key":"10.1002\/14651858.CD004523.pub4-BIB0218|cit218","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1007\/s00198-012-2225-1","article-title":"Long-term mortality following fractures at different skeletal sites: a population-based cohort study","volume":"24","author":"Melton","year":"2013","journal-title":"Osteoporosis International"},{"issue":"5","key":"10.1002\/14651858.CD004523.pub4-BIB0219|cit219","first-page":"658","article-title":"Ranking antireabsorptive agents to prevent vertebral fractures in postmenopausal osteoporosis by mixed treatment comparison meta-analysis","volume":"17","author":"Migliore","year":"2013","journal-title":"European Review for Medical and Pharmacological Sciences"},{"issue":"5","key":"10.1002\/14651858.CD004523.pub4-BIB0220|cit220","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1093\/ije\/21.5.837","article-title":"Intention-to- treat analysis: implications for quantitative and qualitative research","volume":"21","author":"Newell","year":"1992","journal-title":"International Journal of Epidemiology"},{"issue":"6","key":"10.1002\/14651858.CD004523.pub4-BIB0221|cit221","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1001\/jama.285.6.785","article-title":"Osteoporosis prevention, diagnosis, and therapy","volume":"285","author":"NIH Consensus Development Panel on Osteoporosis Prevention","year":"2001","journal-title":"JAMA"},{"key":"10.1002\/14651858.CD004523.pub4-BIB0222|cit222","unstructured":"NOGG 2017: Clinical guideline for the prevention and treatment of osteoporosis National Osteoporosis Guideline Group"},{"issue":"4","key":"10.1002\/14651858.CD004523.pub4-BIB0223|cit223","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1177\/1078155207080806","article-title":"Significance and impact of bisphosphonate-induced acute phase responses","volume":"13","author":"Olson","year":"2007","journal-title":"Journal of Oncology Pharmacy Practice"},{"issue":"9","key":"10.1002\/14651858.CD004523.pub4-BIB0224|cit224","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1007\/s00198-006-0135-9","article-title":"The population burden of fractures originates in women with osteopenia, not osteoporosis","volume":"17","author":"Pasco J","year":"2006","journal-title":"Osteoporosis International"},{"key":"10.1002\/14651858.CD004523.pub4-BIB0225|cit225","unstructured":"WebPlotDigitizer Version: 4.2 Rohatgi A San Francisco, California, USA"},{"key":"10.1002\/14651858.CD004523.pub4-BIB0226|cit226","unstructured":"Sch\u00fcnemann H Bro\u017cek J Guyatt G GRADE handbook for grading quality of evidence and strength of recommendations The GRADE Working Group"},{"issue":"11","key":"10.1002\/14651858.CD004523.pub4-BIB0227|cit227","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1016\/j.amjcard.2014.03.008","article-title":"Risk of atrial fibrillation with use of oral and intravenous bisphosphonates","volume":"113","author":"Sharma","year":"2014","journal-title":"American Journal of Cardiology"},{"issue":"4","key":"10.1002\/14651858.CD004523.pub4-BIB0228|cit228","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1007\/s00198-013-2576-2","article-title":"Comparative gastrointestinal safety of bisphosphonates in primary osteoporosis: a network meta-analysis","volume":"25","author":"Tadrous","year":"2014","journal-title":"Osteoporosis International"},{"issue":"3","key":"10.1002\/14651858.CD004523.pub4-BIB0229|cit229","doi-asserted-by":"crossref","first-page":"262","DOI":"10.4065\/77.3.262","article-title":"Upper gastrointestinal tract safety of risedronate: a pooled analysis of 9 clinical trials","volume":"77","author":"Taggart","year":"2002","journal-title":"Mayo Clinic Proceedings"},{"issue":"9","key":"10.1002\/14651858.CD004523.pub4-BIB0230|cit230","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1002\/jbmr.3118","article-title":"Population-Wide Impact of non-hip non-vertebral fractures on mortality","volume":"32","author":"Tran","year":"2017","journal-title":"Journal of Bone and Mineral Research"},{"key":"10.1002\/14651858.CD004523.pub4-BIB0231|cit231","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.bone.2016.10.013","article-title":"Trends in oral anti-osteoporosis drug prescription in the United Kingdom between 1990 and 2012: variation by age, sex, geographic location and ethnicity","volume":"94","author":"Velde","year":"2017","journal-title":"Bone"},{"key":"10.1002\/14651858.CD004523.pub4-BIB0232|cit232","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1007\/s11657-014-0182-3","article-title":"Estimating prevalence of osteoporosis: examples from industrialized countries","volume":"9","author":"Wade","year":"2014","journal-title":"Archives of Osteoporosis"},{"issue":"5","key":"10.1002\/14651858.CD004523.pub4-BIB0233|cit233","doi-asserted-by":"crossref","first-page":"2787","DOI":"10.1210\/jc.2004-1568","article-title":"Hip fracture in women without osteoporosis","volume":"90","author":"Wainwright","year":"2005","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"10.1002\/14651858.CD004523.pub4-BIB0234|cit234","unstructured":"World Health Organization Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: Report of a WHO study group World Health Organ Technical Report Series: 843 1994"},{"key":"10.1002\/14651858.CD004523.pub4-BIB0235|cit235","unstructured":"WHO scientific group on the assessment of osteoporosis at primary health care level: summary meeting report World Health Organization (WHO)"},{"issue":"2","key":"10.1002\/14651858.CD004523.pub4-BIB0236|cit236","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.bone.2013.09.008","article-title":"Trends in osteoporosis treatment with oral and intravenous bisphosphonates in the United States, 2002-2012","volume":"57","author":"Wysowski","year":"2013","journal-title":"Bone"},{"issue":"3-4","key":"10.1002\/14651858.CD004523.pub4-BIB0237|cit237","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1159\/000453138","article-title":"Network meta-analysis of pharmacological agents for osteoporosis treatment and fracture prevention","volume":"40","author":"Yang","year":"2016","journal-title":"Cellular Physiology and Biochemistry"},{"issue":"11","key":"10.1002\/14651858.CD004523.pub4-BIB0238|cit238","doi-asserted-by":"crossref","first-page":"3289","DOI":"10.1007\/s00198-016-3654-z","article-title":"Comparative efficacy of bisphosphonates in short-term fracture prevention for primary osteoporosis: a systematic review with network meta-analyses","volume":"27","author":"Zhou","year":"2016","journal-title":"Osteoporosis International"},{"key":"10.1002\/14651858.CD004523.pub4-BIB0239|cit239","unstructured":"Wells GA Cranney A Bouchere M Peterson J Shea B Robinson V Bisphosphonates for the primary and secondary prevention of osteoporotic fractures in postmenopausal women: a meta-analysis [Technology report no 69] Ottawa: Canadian Agency for Drugs and Technologies in Health 2006"},{"issue":"4","key":"10.1002\/14651858.CD004523.pub4-BIB0240|cit240","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD004523","article-title":"Risedronate for the prevention and treatment of postmenopausal osteoporosis","author":"Cranney","year":"2003","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"1","key":"10.1002\/14651858.CD004523.pub4-BIB0241|cit241","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD004523.pub2","article-title":"Risedronate for the prevention and treatment of postmenopausal osteoporosis","author":"Cranney","year":"2006","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"1","key":"10.1002\/14651858.CD004523.pub4-BIB0242|cit242","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD004523.pub3","article-title":"Risedronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women","author":"Wells","year":"2008","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","deposited":{"date-parts":[[2022,11,14]],"date-time":"2022-11-14T03:05:47Z","timestamp":1668395147000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD004523.pub4"}},"subtitle":[],"editor":[{"name":"Cochrane Musculoskeletal Group","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2022,5,3]]},"references-count":242,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2022,7]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd004523.pub4","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,3]]}}}